Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)
Clinical trial NCT03291288 · COMPLETED
Trial details
- NCT number
- NCT03291288
- Sponsor
- Daiichi Sankyo
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2018-02-26
- Primary completion
- 2018-09-26
- Enrollment
- 32
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.